Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cannabidiol as a Potential Treatment for Anxiety Disorders

Cannabidiol as a Potential Treatment for Anxiety Disorders Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurotherapeutics Springer Journals

Cannabidiol as a Potential Treatment for Anxiety Disorders

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/cannabidiol-as-a-potential-treatment-for-anxiety-disorders-AvMhkumTbi
Publisher
Springer Journals
Copyright
Copyright © 2015 by The American Society for Experimental NeuroTherapeutics, Inc.
Subject
Biomedicine; Neurosciences; Neurology; Neurosurgery; Neurobiology
ISSN
1933-7213
eISSN
1878-7479
DOI
10.1007/s13311-015-0387-1
pmid
26341731
Publisher site
See Article on Publisher Site

Abstract

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.

Journal

Neurotherapeutics – Springer Journals

Published: Sep 4, 2015

References

  • Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection
    Kroenke, K; Spitzer, RL; Williams, JB; Monahan, PO; Lowe, B
  • Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database
    Khan, A; Leventhal, RM; Khan, S; Brown, WA
  • Quality of life in the anxiety disorders: a meta-analytic review
    Olatunji, BO; Cisler, JM; Tolin, DF
  • Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
    Kessler, RC; Berglund, P; Demler, O; Jin, R; Merikangas, KR; Walters, EE
  • Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication
    Wang, PS; Lane, M; Olfson, M; Pincus, HA; Wells, KB; Kessler, RC
  • Cost of disorders of the brain in Europe 2010
    Gustavsson, A; Svensson, M; Jacobi, F
  • An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder
    Otto, MW; Tuby, KS; Gould, RA; McLean, RY; Pollack, MH
  • Remission rates in patients with anxiety disorders treated with paroxetine
    Ballenger, JC
  • Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial
    Krystal, JH; Rosenheck, RA; Cramer, JA
  • Associations of psychotherapy dose and SSRI or SNRI refills with mental health outcomes among veterans with PTSD
    Shin, HJ; Greenbaum, MA; Jain, S; Rosen, CS
  • Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
    Izzo, AA; Borrelli, F; Capasso, R; Marzo, V; Mechoulam, R
  • Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
    Campos, AC; Moreira, FA; Gomes, FV; Bel, EA; Guimaraes, FS
  • Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
    Schier, ARD; Ribeiro, NP; Silva, AC
  • Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of Cannabis sativa
    Schier, ARD; de Oliveira Ribeiro, NP; Coutinho, DS
  • Endocannabinoid system and mood disorders: priming a target for new therapies
    Micale, V; Marzo, V; Sulcova, A; Wotjak, CT; Drago, F
  • Cannabidiol—recent advances
    Mechoulam, R; Peters, M; Murillo-Rodriguez, E; Hanus, LO
  • Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects
    Marco, EM; Garcia-Gutierrez, MS; Bermudez-Silva, FJ
  • Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
    Devinsky, O; Cilio, MR; Cross, H
  • Cannabinoids and schizophrenia: therapeutic prospects
    Robson, PJ; Guy, GW; Marzo, V
  • Safety and side effects of cannabidiol, a Cannabis sativa constituent
    Bergamaschi, MM; Queiroz, RH; Zuardi, AW; Crippa, JA
  • Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
    McPartland, JM; Duncan, M; Marzo, V; Pertwee, RG
  • Anandamide: Some like it hot
    Marzo, V; Bisogno, T; Petrocellis, L
  • Endocannabinoid signaling in the brain
    Wilson, RI; Nicoll, RA
  • The endocannabinoid system: An overview
    Battista, N; Tommaso, M; Bari, M; Maccarrone, M
  • Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release
    Lee, SH
  • Hot flash: TRPV channels in the brain
    Kauer, JA; Gibson, HE
  • Modulation of defensive behavior by transient receptor potential vanilloid type-1 (TRPV1) channels
    Aguiar, DC; Moreira, FA; Terzian, AL
  • The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders
    Silvestri, C; Marzo, V
  • Endocannabinoid signaling and synaptic function
    Castillo, PE; Younts, TJ; Chavez, AE; Hashimotodani, Y
  • Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it
    Riebe, CJ; Pamplona, FA; Kamprath, K; Wotjak, CT
  • A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior
    McLaughlin, RJ; Hill, MN; Gorzalka, BB
  • The endocannabinoid system: emotion, learning and addiction
    Moreira, FA; Lutz, B
  • The endocannabinoid system in anxiety, fear memory and habituation
    Ruehle, S; Rey, AA; Remmers, F; Lutz, B
  • 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons
    Llorente-Berzal, A; Terzian, AL; di Marzo, V; Micale, V; Viveros, MP; Wotjak, CT
  • The endogenous cannabinoid system controls extinction of aversive memories
    Marsicano, G; Wotjak, CT; Azad, SC
  • FAAH genetic variation enhances fronto-amygdala function in mouse and human
    Dincheva, I; Drysdale, AT; Hartley, CA
  • Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
    Gray, JM; Vecchiarelli, HA; Morena, M
  • Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling
    Evanson, NK; Tasker, JG; Hill, MN; Hillard, CJ; Herman, JP
  • Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory
    Abush, H; Akirav, I
  • Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress
    Hill, MN; Patel, S; Carrier, EJ
  • Chronic stress induces anxiety via an amygdalar intracellular cascade that impairs endocannabinoid signaling
    Qin, Z; Zhou, X; Pandey, NR
  • The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD
    Neumeister, A
  • Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research
    Papini, S; Sullivan, GM; Hien, DA; Shvil, E; Neria, Y
  • Investigational drugs under development for the treatment of PTSD
    Ragen, BJ; Seidel, J; Chollak, C; Pietrzak, RH; Neumeister, A
  • Endocannabinoid system and stress and anxiety responses
    Viveros, MP; Marco, EM; File, SE
  • Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex
    Rubino, T; Realini, N; Castiglioni, C
  • Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin?
    Moreira, FA; Aguiar, DC; Terzian, AL; Guimaraes, FS; Wotjak, CT
  • Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
    Bisogno, T; Hanus, L; De Petrocellis, L
  • Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats
    Haller, J
  • Cooperative regulation of anxiety and panic-related defensive behaviors in the rat periaqueductal grey matter by 5-HT1A and mu-receptors
    Roncon, CM; Biesdorf, C; Coimbra, NC
  • Activation of postsynaptic 5-HT1A receptors improve stress adaptation
    Zhou, J; Cao, X; Mar, AC
  • Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation
    Saito, Y; Matsumoto, M; Yanagawa, Y
  • Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists
    Sprouse, JS; Aghajanian, GK
  • Activation of 5-HT receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease
    Sun, YN; Wang, T; Wang, Y
  • Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research
    Celada, P; Bortolozzi, A; Artigas, F
  • Agonistic properties of cannabidiol at 5-HT1a receptors
    Russo, EB; Burnett, A; Hall, B; Parker, KK
  • Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus
    Rock, EM; Bolognini, D; Limebeer, CL
  • Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior
    Silveira Filho, NG; Tufik, S
  • Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol
    Zuardi, AW; Finkelfarb, E; Bueno, OF; Musty, RE; Karniol, IG
  • Pharmacological characterization of cannabinoids in the elevated plus maze
    Onaivi, ES; Green, MR; Martin, BR
  • Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
    Moreira, FA; Aguiar, DC; Guimaraes, FS
  • Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
    Resstel, LB; Joca, SR; Moreira, FA; Correa, FM; Guimaraes, FS
  • Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
    Campos, AC; Guimaraes, FS
  • Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats
    Bitencourt, RM; Pamplona, FA; Takahashi, RN
  • Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids
    Campos, AC; Guimaraes, FS
  • 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
    Resstel, LB; Tavares, RF; Lisboa, SF
  • Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
    Soares Vde, P; Campos, AC; Bortoli, VC
  • A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice
    Long, LE; Chesworth, R; Huang, XF
  • Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats
    Lemos, JI; Resstel, LB; Guimaraes, FS
  • Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
    Casarotto, PC; Gomes, FV; Resstel, LB; Guimaraes, FS
  • The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
    Gomes, FV; Resstel, LB; Guimaraes, FS
  • Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress
    Granjeiro, EM; Gomes, FV; Guimaraes, FS; Correa, FM; Resstel, LB
  • Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour
    Deiana, S; Watanabe, A; Yamasaki, Y
  • Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm
    Uribe-Marino, A
  • On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment
    Stern, CA; Gazarini, L; Takahashi, RN; Guimaraes, FS; Bertoglio, LJ
  • Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors
    Campos, AC; Ferreira, FR; Guimaraes, FS
  • Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats
    Hsiao, YT; Yi, PL; Li, CL; Chang, FC
  • Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors
    Gomes, FV; Resstel, LB; Guimaraes, FS
  • Anxiogenic-like effects of chronic cannabidiol administration in rats
    Batsh, MM; Assareh, N; Marsden, CA; Kendall, DA
  • The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
    Campos, AC; Ortega, Z; Palazuelos, J
  • Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors
    Do Monte, FH; Souza, RR; Bitencourt, RM; Kroon, JA; Takahashi, RN
  • Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats
    Campos, AC; de Paula Soares, V; Carvalho, MC
  • Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
    Almeida, V; Levin, R; Peres, FF
  • Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT(1)A receptor
    Gomes, FV; Alves, FH; Guimaraes, FS
  • The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae)
    Twardowschy, A; Castiblanco-Urbina, MA; Uribe-Marino, A
  • Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience
    Fogaca, MV; Reis, FM; Campos, AC; Guimaraes, FS
  • Cannabidiol reverses the mCPP-induced increase in marble-burying behavior
    Nardo, M; Casarotto, PC; Gomes, FV; Guimaraes, FS
  • Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB-cannabinoid receptor in the ventral mesencephalon
    Silva, JA; Biagioni, AF; Almada, RC
  • Antianxiety effect of cannabidiol in the elevated plus-maze
    Guimaraes, FS; Chiaretti, TM; Graeff, FG; Zuardi, AW
  • Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?
    Bandler, R; Shipley, MT
  • Sensations evoked by stimulation in the midbrain of man
    Nashold, BS; Wilson, WP; Slaughter, DG
  • Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses
    Walker, DL; Miles, LA; Davis, M
  • Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear
    Sierra-Mercado, D; Padilla-Coreano, N; Quirk, GJ
  • Modeling panic attacks
    Schenberg, LC; Bittencourt, AS; Sudre, EC; Vargas, LC
  • Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety
    Thomas, A; Burant, A; Bui, N; Graham, D; Yuva-Paylor, LA; Paylor, R
  • Memory reconsolidation and extinction have distinct temporal and biochemical signatures
    Suzuki, A; Josselyn, SA; Frankland, PW
  • Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects
    Zuardi, AW; Shirakawa, I; Finkelfarb, E; Karniol, IG
  • Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man
    Karniol, IG; Shirakawa, I; Kasinski, N; Pfeferman, A; Carlini, EA
  • Effects of ipsapirone and cannabidiol on human experimental anxiety
    Zuardi, AW; Cosme, RA; Graeff, FG; Guimaraes, FS
  • Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers
    Martin-Santos, R; Crippa, JA; Batalla, A
  • Effects of cannabidiol (CBD) on regional cerebral blood flow
    Crippa, JA; Zuardi, AW; Garrido, GE
  • Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology
    Bhattacharyya, S; Morrison, PD; Fusar-Poli, P
  • Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
    Crippa, JA; Derenusson, GN; Ferrari, TB
  • Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients
    Bergamaschi, MM; Queiroz, RH; Chagas, MH
  • Cannabidiol enhances consolidation of explicit fear extinction in humans
    Das, RK; Kamboj, SK; Ramadas, M
  • Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users
    Hindocha, C; Freeman, TP; Schafer, G
  • Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition
    Borgwardt, SJ; Allen, P; Bhattacharyya, S
  • Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol
    Fusar-Poli, P; Allen, P; Bhattacharyya, S
  • Inhibitory neural activity predicts response to cognitive-behavioral therapy for posttraumatic stress disorder
    Falconer, E; Allen, A; Felmingham, KL; Williams, LM; Bryant, RA
  • A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis
    Mochcovitch, MD; Rocha Freire, RC; Garcia, RF; Nardi, AE
  • Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies
    Patel, R; Spreng, RN; Shin, LM; Girard, TA
  • Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis
    Morgan, CJ; Freeman, TP; Schafer, GL; Curran, HV
  • Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
    Morgan, CJ; Curran, HV
  • Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]
    Morgan, CJ; Schafer, G; Freeman, TP; Curran, HV
  • Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol
    Demirakca, T; Sartorius, A; Ende, G
  • Does cannabidiol protect against adverse psychological effects of THC?
    Niesink, RJ; Laar, MW
  • PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program
    Greer, GR; Grob, CS; Halberstadt, AL
  • Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence
    Passie, T; Emrich, HM; Karst, M; Brandt, SD; Halpern, JH